GSK announces new joint venture in emerging vaccine market – are joint ventures critical?

emerging markets vaccines

With GlaxoSmithKline (GSK) recently announcing an agreement to form a joint venture with Indian vaccine company Biological E, this may be a sign that innovative collaborations are becoming more critical for building presence in emerging markets.

GSK and Biological E have established a 50/50 joint venture to develop a 6-in-1 vaccine that combines GSK's injectable polio vaccine with Biological E's vaccine for diptheria, tetanus, whooping cough, hepatitis B and Haemophilus influenzae b. The vaccine is expected to enter Phase I in the next two years.

This joint venture joins a growing list of collaborations between multinational drugmakers and local companies, including a Cooperation Agreement between GSK and Shenzhen Neptunus Interlong Bio-Technique Co. Ltd to develop a flu vaccine in China, and a partnership between Pfizer and Shanghai Pharmaceutical to deliver Prevnar to the Chinese market. Rather than making outright acquisitions, multinationals might be looking more towards joint ventures to leverage the position the local company already has in the market.

How important do you think joint ventures are for multinational drugmakers to break into the emerging markets?

Do you think we will see more joint ventures in the vaccine market in the near future?

Why not join our discussion on LinkedIn, or leave a comment below. I'd love to hear your thoughts.

If you'd like to hear more about strategy and innovation in vaccines, you are welcome to attend the World Vaccine Congress & Expo 2013, 16-18 April 2013 at the Gaylord National Hotel and Convention Center, Washington DC.

Leave a Reply

Your email address will not be published. Required fields are marked *